Patient-reported attack history shows patients treated with current injectable or infused prophylactic medications (Takhzyro, Haegarda, Cinryze) continue to experience breakthrough attacks with a mean ranging from 0.9 to 1.8 attacks over the three months prior to survey.
In addition, the majority of patients surveyed did not expect to have zero attacks even when taking prophylaxis therapy.
The data were presented at the
'While the injectable and infused medications introduced over the past 12 years have provided added prophylactic attack control for HAE patients, most patients in the study continue to experience breakthrough attacks, and medication adherence continues to be a challenge. HAE patients have indicated an interest in new preventative treatment options, with the majority agreeing that they would prefer an oral medication, despite liking their current prophylactic medication,' said
Study Methods and Results
Study participants were
In the 2019 survey, 85 percent of patients reported taking at least one medicine to prevent HAE attacks, compared to 64 percent in the 2018 survey.
The majority (89 percent) of patients using prophylaxis in the 2019 survey reported using at least one of the three most commonly prescribed injectable or infused prophylactic therapies.
Over the three months prior to the survey, these patients reported a mean of 0.9, 1.6 and 1.8 attacks while taking Haegarda, Cinryze and Takhzyro, respectively. Patients taking these injectable or infused therapies reported similar attack rates in the 2018 study.
In the 2019 survey, 21 percent of patients using prophylaxis reported the expectation to have zero attacks over the next 12 months.
About
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst's actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that the ongoing COVID-19 pandemic could create challenges in all aspects of our business, including without limitation delays, stoppages, difficulties and increased expenses with respect to our and our partners' development, regulatory processes and supply chains, could negatively impact our ability to access the capital or credit markets to finance our operations, or could have the effect of heightening many of the risks described below or in the documents we file periodically with the
Contact:
Tel: +1 919 859 7910
Email: jbluth@biocryst.com
(C) 2020 Electronic News Publishing, source